| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 45629-0134-01 | 45629-0134 | Tivozanib | FOTIVDA | 1.34 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Mar 10, 2021 | In Use | |
| 46708-0566-30 | 46708-0566 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jul 9, 2021 | In Use | |
| 71777-0392-01 | 71777-0392 | LAROTRECTINIB | VITRAKVI | 20.0 mg/mL | Chemotherapy | Tyrosine Kinase Inhibitor | TRK | Oral | Nov 26, 2018 | In Use | |
| 66993-0236-30 | 66993-0236 | Dasatinib | Dasatinib | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 3, 2024 | In Use | |
| 70377-0084-11 | 70377-0084 | Dasatinib | Dasatinib | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
| 50419-0171-03 | 50419-0171 | Regorafenib | Stivarga | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl | Oral | Sep 27, 2012 | In Use | |
| 68382-0245-16 | 68382-0245 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 21, 2021 | In Use | |
| 63304-0093-27 | 63304-0093 | Sunitinib malate | Sunitinib malate | 37.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Dec 25, 2019 | In Use | |
| 00078-1091-20 | 00078-1091 | asciminib | SCEMBLIX | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct 29, 2021 | In Use | |
| 00069-0197-30 | 00069-0197 | Dacomitinib | Vizimpro | 15.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Oct 4, 2018 | Dec 31, 2029 | In Use |
| 62332-0312-30 | 62332-0312 | Bosutinib | Bosutinib | 500.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 19, 2026 | In Use | |
| 24338-0155-01 | 24338-0155 | Nilotinib | DANZITEN | 95.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 30, 2024 | In Use | |
| 69097-0032-74 | 69097-0032 | Nilotinib | Nilotinib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 18, 2025 | In Use | |
| 60505-4512-03 | 60505-4512 | Gefitinib | Gefitinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Aug 8, 2023 | Dec 31, 2025 | No Longer Used |
| 59651-0546-15 | 59651-0546 | DASATINIB | DASATINIB | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 22, 2025 | In Use | |
| 70771-1395-08 | 70771-1395 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 21, 2021 | In Use | |
| 62856-0724-05 | 62856-0724 | Lenvatinib | Lenvima | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, RET | Oral | Feb 13, 2015 | In Use | ||
| 50881-0028-01 | 50881-0028 | Pemigatinib | PEMAZYRE | 13.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR1, FGFR2, FGFR3 | Oral | Apr 17, 2020 | In Use | |
| 62856-0714-30 | 62856-0714 | Lenvatinib | Lenvima | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, RET | Oral | Feb 13, 2015 | In Use | ||
| 72730-0202-01 | 72730-0202 | infigratinib | TRUSELTIQ | 75.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | May 28, 2021 | In Use | |
| 57962-0280-28 | 57962-0280 | Ibrutinib | IMBRUVICA | 280.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Feb 16, 2018 | In Use | |
| 54868-5289-00 | 54868-5289 | Imatinib Mesylate | Gleevec | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Oct 7, 2005 | Jun 30, 2013 | No Longer Used | |
| 63020-0040-12 | 63020-0040 | Mobocertinib | EXKIVITY | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Sep 15, 2021 | Mar 31, 2025 | No Longer Used |
| 13668-0682-30 | 13668-0682 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF | Oral | Apr 12, 2023 | In Use | |
| 71777-0390-01 | 71777-0390 | LAROTRECTINIB | VITRAKVI | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRK | Oral | Nov 26, 2018 | In Use |
Found 12482 results — Export these results
Home